PARAGANGLIOMA

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be surgically removed. The goal is to see if the drug can slow or stop tumor growth and to check its safety. Participants receive four doses about…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a new treatment called [212Pb]VMT-α-NET for people with advanced tumors that have a specific marker (SSTR2). The treatment delivers targeted radiation to kill cancer cells while sparing healthy tissue. The study involves up to 300 adults with neuroendocrine tumor…

This study is for children and teens (ages 3–18) whose solid tumors have come back or not responded to standard treatment. The therapy combines a radioactive drug (Lutathera) that targets specific receptors on tumor cells with a pill (olaparib) that may make the radiation more ef…

This study is testing whether a special type of PET/MRI scan (using a radioactive tracer called 68Ga-DOTATATE) can better detect brain tumors, especially meningiomas, and tell the difference between tumor regrowth and changes from previous treatment. About 200 adults with certain…

This study aims to see if special PET scans using different radioactive tracers can accurately find and stage neuroblastoma and pheochromocytoma/paraganglioma tumors. About 30 people aged 1 to 70 with suspected or confirmed disease will receive an injection of a tracer and then h…

This study aims to find the genes that cause pheochromocytoma and paraganglioma, rare tumors of the nervous system. Researchers will analyze DNA from up to 2,000 patients and their family members to link specific genetic changes to tumor development. The goal is to improve geneti…

This study tests a new PET scan tracer (18F-FluorThanatrace) to measure PARP-1 protein levels in people with rare adrenal tumors called pheochromocytoma or paraganglioma. About 30 adults will get one scan before their usual treatment. The scan results won't change their care—the …

This study is creating a large database to collect information about people with rare diseases like amyloidosis, sarcoidosis, and many others. Researchers will track participants' health, treatments, and outcomes over time to better understand these conditions. The goal is to imp…